参芪注射液联合半剂量紫杉醇对晚期胃癌近期疗效及血清白细胞介素-2水平的影响

目的观察参芪注射液联合半剂量紫杉醇治疗晚期胃癌的近期疗效。方法采用参芪注射液联合半剂量紫杉醇治疗25例晚期胃癌，每疗程第1天紫杉醇45mg／m2持续静脉滴注3h；参芪注射液250ml／d，静脉滴注第1～14d，间歇1周；每3周为1疗程，共3个疗程。观察疗效和患者血清白细胞介素-2水平变化。结果完全缓解（CR）1例，部分缓解（PR）13例，稳定11例，总有效率56．O％；主要毒性反应为白细胞减少21例（84．O％），脱发19例（76．0％），肌肉关节痛17例（68．O％），无治疗相关性死亡；治疗后患者血清白介素-2明显升高（P〈O．01）。结论参芪注射液联合半剂量紫杉醇治疗晚期胃癌，近期疗效明显，未增加毒副反应，且可显著改善患者细胞免疫功能。

The recent therapeutic efficacy of ShenQi injection combined with half-dose paclitaxel on the patients with advanced gastric cancer

Objective To observer the recent therapeutic efficacy of ShenQi injection combined with half-dose paclitaxel （PTX） in the patients with advanced gastr/c cancer. Methods Twenty -five patients with advanced gastric cancer received half-dose PTX （ 45 mg/m2 , iv infusion,on day 1 ,every three weeks for one cycle） and ShenQi injection（250 ml/d,iv infusion, fi-om day 1 to day 14, every cycle）. All patients were evaluated after three cycles. Results Of the 25 patients, the response rate was 56. 0% （ 14/25 ）. The severe side-effects had not be observed. The level of cytokine interleukin-2 after treatment was （97. 87 ± 21.31 ） ng/L which significantly higher than that before treatment （ P 〈 0. 01 ）. Conclusions Shen Qi injection combined with half-dose PTX is effective, safe, and this therapy can improve cyto-immune function on patients with advanced gastric cancer.